Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

The results of a late-stage drug trial released Thursday are raising hopes that type 1 diabetes patients with chronic kidney ...

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...

Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but ...

Renal cell carcinoma (RCC) comprises a heterogeneous group of neoplasms with variable prognoses. Chromophobe RCC, a relatively uncommon subtype, generally follows an indolent clinical course but may ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 ...

NUTLEY, N.J., Nov. 3, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research in gynecologic oncology during the International Gynecologic Cancer Society (IGCS) 2025 Annual ...

LG Chem will introduce a promising new drug that is expected to have a synergy effect with the kidney cancer treatment 'FOTIVDA, ingredient name: Tivozanib' sold in the United States. LG Chem ...

A Northwestern team transformed a common chemotherapy drug into a powerful, targeted cancer therapy using spherical nucleic ...

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...